Search the Newsreel

Mirum Pharmaceuticals (Nasdaq: MIRM) takes $857M H1 2026 net loss

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

- Q2 2026 net product sales of $176 million - 2026 net product sales guidance increased to $680 million to $700 million - Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC - Pre-NDA meeting held for volixibat in …

Mirum Pharmaceuticals (MIRM) SVP sells 1,840 shares under 10b5-1 plan

Jolanda Howe, SVP and Global Controller at Mirum Pharmaceuticals (MIRM), sold 1,840 shares of common stock on August 3, 2026, at a price of $105.29 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following …

Mirum Pharmaceuticals (MIRM) Earnings Date and Reports 2026

Mirum Pharmaceuticals (MIRM) announced its Q2 2026 earnings on August 5, 2026, reporting an EPS of -$1.06, missing the consensus estimate of -$0.74. Despite the EPS miss, quarterly revenue increased by 37.9% year-over-year to $176.24 million, exceeding the consensus estimate of $166.33 million. The …

Mirum Pharmaceuticals Q2 Loss Widens, Revenue Rises; Shares Fall

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

MIRM (NASDAQ: MIRM) holder files notice to sell common shares

A holder of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) common stock has filed a notice to sell 1,840 shares through Morgan Stanley Smith Barney LLC on or after August 3, 2026. The filing also reports prior sales by Jolanda Marie Howe, including 2,721 shares on …

Mirum Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) generated $521.31 million in revenue last year, primarily from its Pharmaceutical segment. This represents an increase from $336.41 million in the previous year. The United States was the largest contributor to revenue, accounting for $401.55 million last year.

MIRM5806400 Bond Coupon Profile — Rate & Payments

This page provides the bond coupon profile for Mirum Pharmaceuticals, Inc. (MIRM5806400), detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.00%, with the next payment planned for November 2, 2026. It offers an overview of the bond's …

Liquidity Mapping Around (MIRM) Price Events

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) is showing weak near and mid-term sentiment, despite a positive long-term outlook. AI models have generated three distinct trading strategies for MIRM, including position trading, momentum breakout, and risk hedging, with detailed entry points, targets, and stop losses. The …

Hear Mirum Pharmaceuticals' second-quarter update Aug. 5

Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will report its second-quarter 2026 financial results on August 5, 2026. The company will also host a conference call on the same day to discuss these results and recent corporate developments. Mirum Pharmaceuticals is a rare disease company …

Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis

Mirum Pharmaceuticals Inc (MIRM) has a current valuation score of 9.66, placing it 11th out of 155 companies in the Pharmaceuticals industry. Its P/E ratio is -7.91, which is below its recent high and above its recent low. However, relevant data for P/B, P/S, …

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals (Nasdaq: MIRM) will announce its second-quarter 2026 financial results on August 5, 2026. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results and recent corporate developments. Mirum is a rare disease …

Mirum Pharmaceuticals Q2 Results: Earnings call set for Aug 5, 2026

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) will release its Q2 2026 financial results on August 5, 2026, followed by a conference call at 4:30 p.m. ET to discuss the quarterly figures and recent corporate progress. The rare disease company will provide investors with insights into …

Mirum Pharmaceuticals earnings in focus as pipeline expands

Mirum Pharmaceuticals is poised to report its second-quarter earnings, with analysts anticipating a significant sequential improvement in both revenue and a reduced loss per share. Investors will be closely watching the company's progress towards its full-year revenue guidance, the commercial performance of LIVMARLI, and …

Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Mirum Pharmaceuticals Inc (MIRM), listing major individual and institutional holders and their respective proportions. It also presents institutional shareholding trends over several quarters and highlights related ETFs that hold MIRM. Key information includes top shareholders like Frazier …

Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Mirum Pharmaceuticals Inc (MIRM) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page displays current stock metrics such as market capitalization …

Mirum Pharmaceuticals, Inc. Revenue Breakdown – BIVA:MIRM

Mirum Pharmaceuticals, Inc. (MIRM) generated 9.40 billion MXN in total revenue last year, primarily from its Pharmaceutical segment. The United States was the largest contributor to its revenue, accounting for 7.24 billion MXN. This represents an increase from the previous year's revenue of 7.01 …

Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails

Stifel maintained its Buy rating and $136.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM) following the failure of a competitor's Phase 3 clinical trial in biliary atresia. The firm noted that Mirum's own EXPAND study, with data expected in Q4 2026, is de-risked and sees …

MIRM|Mirum Pharmaceuticals Inc|Price:113.030|Chg%:-1.330

Mirum Pharmaceuticals Inc. (MIRM) closed at $113.03, down 1.16%, with a market cap of $6.89B. The company, focused on rare disease treatments, is considered to have healthy fundamentals, high growth potential, and a fairly valued assessment, with a strong buy rating from analysts. Its …

MIRM Financials

Mirum Pharmaceuticals Inc. (MIRM) closed at $113.030 with a -1.16% change. The article provides a comprehensive financial overview of Mirum Pharmaceuticals Inc., detailing its income statement, balance sheet, and cash flow statement through Q1 2026 and historical data. It also highlights key financial indicators, …

Mirum Pharmaceuticals (MIRM) Projected to Announce Quarterly Earnings on Thursday

Mirum Pharmaceuticals (MIRM) Stock Looks Fully Valued On Current Sales Expectations

Mirum Pharmaceuticals (MIRM) stock is considered overvalued based on current sales expectations, despite a 7x return for investors over the past five years. The company trades at a P/S multiple of 12.3x compared to an industry average of 10.9x and a tailored fair multiple …

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Exploring a 25.62% Potential Upside in the Biotech Arena

Mirum Pharmaceuticals, Inc. (MIRM) is highlighted as a compelling investment opportunity in the biotechnology sector, focusing on rare and orphan diseases. Despite a recent price dip, analysts project a 25.62% upside from its current stock price of $116.62, with an average target price of …

Why (MIRM) Price Action Is Critical for Tactical Trading

This article analyzes Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) for tactical trading, highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It details institutional trading strategies, including long, breakout, and short positions, alongside multi-timeframe signal analysis to guide traders on potential price movements.

MIRM5806400 Bond Risk Profile

This article provides an overview of the MIRM5806400 bond issued by Mirum Pharmaceuticals, Inc. The bond has a 4.0% coupon and matures on May 1, 2029. It outlines key metrics for risk analysis, including security level, inflation protection, and issuer rating to help evaluate …

US604749AB7 Bond Profile — Key Metrics

This article provides key metrics for the Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029 bond (US604749AB7). It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Mirum Pharmaceuticals, Inc. is described as a biopharmaceutical company focused on liver disease therapies.